Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Q2 Preview: Where Is The Next Blockbuster Coming From?

Hoping For Recovery from COVID-19 Pressure

Executive Summary

Entresto and Cosentyx continue to grow but investors will be looking to see if there are candidates in the current portfolio or pipeline that could join them in the mega-blockbuster club.

You may also be interested in...



Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success

The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.

Lilly/BI's Jardiance Scores A Win In Heart Failure Where Rivals Have Not

A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.

Novartis Challenger To Alexion Advances In Rare Kidney Disease

First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel